The CanceRx DifferenceCanceRx Improves
CanceRx Improves
R&D Financing
Unlike traditional venture capital, which prioritizes profit and ROI timelines, CanceRx uses long-duration funding to support clinical development and FDA submissions. Successful drugs are licensed to drug companies for further development. This fits how pharma prefers to obtain new drugs and scale up product manufacturing, regulatory approval and launch.
How Does This Improve Cancer Research?
The CanceRx approach enables a host of improvements in research outcomes:
Lowering cost of discovery
Tapping into thousands of already-discovered products saves hundreds of millions of dollars.
Lowering risk
More drugs in the pipeline improves the odds of finding success.
Reducing R&D costs
Lowering the cost of clinical trials helps put more new drugs into testing.
Incentive
Revenue is based on finding new cures, not grants or service fees.
Eliminating bottlenecks
Stable financing clears obstacles in funding research.
Better medicine
Improving cancer detection, treatment and survival saves more lives and makes healthcare more effective.
The CanceRx DifferenceLeveraging Financial and
Leveraging Financial and
Technology-Driven Innovation
Long-Term Financing For Clinical Trials
Providing steady funding for clinical development.
Results-Driven Portfolio Management
Driving trial design and conduct.
Expanded Patient Treatment Options
Improving patient access to clinical trials.
Getting In Touch
We encourage you to reach out with questions about CanceRx.
By submitting this form, you are consenting to receive marketing emails from: CanceRx. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact